Centre du Cancer Lausanne




Home < Centre de recherche < Publications 2010 < Publications 2004

Publications 2010

Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

	Publications 2004

Publications 2003

Publications 2002

Publications 2001

Info.onco@chuv.ch

Publications : 2004
1:	Agazzi S, Pampallona S, Pica A, Vernet O, Regli L, Porchet F, Villemure JG, Leyvraz S. (2004).
		The origin of brain metastases in patients with an undiagnosed primary tumour. Acta Neurochir (Wien) 146(2): 153-7.
2:	Ataman F, Poortmans P, Stupp R, Fisher B, Mirimanoff RO. (2004).
		Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. Eur J Cancer 40(11): 1724-30.
3:	Bauer J.
		Cancer de la Vessie Médecine&Hygiène 2482,12 mai 2004, 1049-52.
4:	Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C.
		Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004 Nov 29;91(11):1893-901.
5:	Broillet, J. Hantson, C. Ruegg, T. Messager, and M. Schneider.
		Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue™ to monitor the effects of different anti-angiogenic therapies Acad. Radiol. In press
6:	Calzascia T, W. Besson, F. Masson, E. Contasso, R. Wilmotte, A. Aurrand-Lions, C. Rüegg, P-Y. Dietrich and P. Walker.
		Brain infiltrating tumor-specific CD8 T cells exhibit a unique phenotype imprinted in cervical lymph nodes and modulated in the cerebral parenchyma. Immunity In press
7:	Delaloye J, Merlani G, Petignat C, Wenger A, Zaman K, Monnerat C, Matzinger O, Nenadov Beck M, Vuichard P, Ketterer N, Tarr PE.
		Nosocomial Nontyphoidal Salmonellosis after Antineoplastic Chemotherapy: Reactivation of asymptomatic colonization? Eur J Clin Microb Infect Dis 2004;23:751-8.
8:	Dormond O., M. Hasmim, L. Ponsonnet, A. Foletti and C. Rüegg (2004).
		Manganese-induced integrin affinity maturation promotes aVb3 recruitment to focal adhesions in endothelial cells through phosphatidylinositol 3-kinase-dependent signaling Thromb.Haemost., 92:151-61.
9:	Foletti A., G-C. Alghisi, L. Ponsonnet and C. Rüegg.
		Isolated integrin b1 and b3 subunit cytoplasmic domains require membrane anchorage to recruit to adhesion complexes but cannot discriminate between b1+-fibrillar adhesions and b3+-focal adhesions Thromb. Haemost., In revision
10:	Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. (2005).
		Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23(4): 705-11.
11:	Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T. (2004).
		Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103(12): 4416-23.
12:	Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, Schnyder P, Luthi F, von Schulthess GK, Leyvraz S. (2005)
		The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32(2): 153-62.
13:	Hasmim M., G. Vassalli, L. Ponsonnet, G. Vassalli, J. Bamat, C. Bieler, J. Paroz, D. Oguey, and C. Rüegg.
		Endothelial cell death induced by expression of isolated integrin b1 subunit cytoplasmic domain in vitro and in vivo is secondary to cell detachment. (Submitted)
14:	Hauert J, Fernandez-Carneado J, Michielin O, Mathieu S, Grell D, Schapira M, Spertini O, Mutter M, Tuchscherer G, Kovacsovics T.
		A template-assembled synthetic protein surface mimetic of the von Willebrand factor A1 domain inhibits botrocetin-induced platelet aggregation. Chembiochem. 2004 Jun 7;5(6):856-64.
15:	Hegi M.E, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. (2004).
		Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10(6): 1871-4.
16:	Hegi M.E., A.-Cl. Diserens, Th. Gorlia, M.-F. Hamou, N. de Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, Jacoline EC Bromberg, P. Hau, R.-O. Mirimanoff, G Cairncross, R.C. Janzer, R. Stupp.
		MGMT Gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352, 997-1003, 2005.
17:	Horisberger JD, Kharoubi-Hess S, Guennoun S, Michielin O.
		The fourth transmembrane segment of the Na,K-ATPase alpha subunit: a systematic mutagenesis study. J Biol Chem. 2004 Jul 9;279(28):29542-50. Epub 2004 Apr 28.
18:	Jermann M, Stahel R, Salzberg M, Cerny T, Jorger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA et al.
		A phase II, open-label study of Gefitinib (Iressa) in patients with locally advanced, metastatic, or relapsed renal carcinoma. (Submitted)
19:	Kalyuzhniy O.S., S. Potekhin, G. Corradin, A. Kayawa and C. Rüegg.
		A novel RGD-containing coiled-coils self assembling fibril peptide support s cell adhesion. (Submitted)
20:	Kleeberg UR, Suciu S, Brocker EB, Ruiter DJ, Chartier C, Lienard D, Marsden J, Schadendorf D, Eggermont AM; EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). (2004).
		Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40(3): 390-402.
21:	Koeberle D, Perey L, Thuerlimann B; Swiss Group for Clinical Cancer Research (SAKK).
		Re: Playing the old piano: another tune for endocrine therapy. J Natl Cancer Inst. 2004 Apr 7;96(7):555-6; author reply 556-7.
22:	Kutter J, Ozsahin M, Monnier P, Stupp R. (2004).
		Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol, 262 : 1-7, 2005
23:	Lamy O. Elmiger H. Fiche M. Bauer J. Livio F.
		Acquired hemophilia as first manifestation of breast carcinoma in a man under long-term spironolactone therapy. [Case Reports. Journal Article] International Journal of Clinical Oncology. 9(2):130-3, 2004 Apr. Le traitement médicamenteux des Cancers. Actualisation de la brochure de la ligue suisse contre le cancer 2004
24:	Lejeune FJ, Leyvraz S.
		Quelle est la place des traitements intravasculaires hépatiques pour métastases ? Médecine et Hygiène, 62 : 1219-24, 2004.
25:	Li C, Grosdidier A, Crambert G, Horisberger JD, Michielin O, Geering K.
		Structural and functional interaction sites between Na,K-ATPase and FXYD proteins. J Biol Chem. 2004 Sep 10;279(37):38895-902. Epub 2004 Jul 2.
26:	Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. (2004).
		"Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA." Cancer Immun 4: 4.
27:	Michielin O, Udry E, Periard D, Matzinger O, Lobrinus JA, Stupp R. (2004).
		Irinotecan-induced interstitial pneumonia. Lancet Oncol 5(5): 322-4.
28:	Monnier Y., J. Zaric and C. Rüegg
		Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the bench to the bedside and back. Curr Drug Targets, In press
29:	Morant, R, Bernhard, J, Dietrich D, Gillessen S, Bonomo M, Borner M, Bauer J
		Capecitabine in Hormone-resistant metastatic prostatic carcinoma a Phase II trial. et al British J Cancer 2004 90,1312-1317.
30:	Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Lienard D, Gugerli O, Ferradini L, Robert C, Avril MF, Zitvogel L, Angevin E. (2004).
		Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res 64(6): 2192-8.
31:	Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R. (2004).
		Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10(11): 3728-36.
32:	Rüegg C., O. Dormond and A. Mariotti (2004)
		Endothelial cell integrins and COX-2: Mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta Rev Cancer 1654, 51-67.
33:	Rollini, P., S. Kaiser, et al. (2004).
		Long-term expansion of transplantable human fetal liver hematopoietic stem cells. Blood 103(3): 1166-70.
34:	Rossi CR, Testori A, Mocellin S, Campana L, Lejeune F. (2004).
		Melanoma - what is new in sentinel node biopsy and locoregional treatments in 2003? Report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003. Melanoma Res 14(5): 329-32.
35:	Rosti G, De Giorgi U, Wandt H, Lioure B, Leyvraz S, Kolbe K, Papiani G, Ballardini M, Kulekci A, Demirer T; Solid Tumours Working Party. (2004).
		First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant 34(12): 1033-7.
36:	Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F.. (2004).
		5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 15(5): 759-64.
37:	Sabbioni ME, Bernhard J, Siegrist HP, Schmitz SF, Gertsch MC, Thurlimann B, Bonnefoi H, Perey L, Herrmann R, Goldhirsch A, Hurny C; Swiss Group for Clinical Cancer Research (SAKK).
		Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast Cancer Res Treat. 2004 Sep;87(1):75-86.
38:	Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'o E, Colombo N.
		Trabectedin (ET743) for women with ovarian cancer after failure of platinum-taxane. JCO (accepted for publication).
39:	Siegenthaler MA, Vu DH, Ebnother M, Ketterer N, Luthi F, Schmid P, Bargetzi M, Gasparini D, Tissot JD. (2004).
		'Agglutination and flocculation' of stem cells collected by apheresis due to cryofibrinogen. Bone Marrow Transplant 33(7): 765-7.
40:	Stupp R, W.P. Mason, J.J. van den Brent, et al.
		Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352 : 987-96, 2005
41:	Stupp, R., C. Monnerat, et al. (2004).
		Small cell lung cancer: state of the art and future perspectives. Lung Cancer 45(1): 105-17.
42:	Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A
		Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res Treat. 2004 Jun;85(3):247-54.
43:	Thurlimann B, Hess D, Koberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A., van den Bent, M. J., R. Stupp. (2004).
		Current and future trials of the EORTC brain tumor group. Onkologie 27(3): 246-50.
44:	Wasserfallen JB, Ostermann S, Pica A, Mirimanoff RO, Leyvraz S, Villemure JG, Stupp R. (2004).
		Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer 101(9): 2098-105.
45:	Wasserfallen JB, Ostermann S, Pica A, Mirimanofff RO, Leyvraz S, Villemure JG, Stupp R .
		Cost of temozolomide therapy and global care for recurrent malignant glioma followed until death. Neuro-Oncology, 2005, in press.
46:	Widmer N, Beguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, Leyvraz S, Rosselet A, Biollaz J, Decosterd LA. (2004).
		Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 803(2): 285-92.
47:	Zaman K., R. Driscoll, P. Werffeli, J. Bauer, S. Leyvraz, F. Lejeune, R. Stupp, and C. Rüegg.
		Monitoring multiple angiogenesis-related molecules in the blood of cancer patients before and after treatment reveals differential patterns and behaviors and association between VEGF and MMP-9. Clin. Cancer Res., In revision
48:	Zaric J., and C. Rüegg.
		Integrin-mediated adhesion induces COX-2 activity by promoting COX-2 protein stability (2005) J. Biol. Chem., 14;280: 1077-85 Epub 4 Nov 2004
49:	Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ. (2004).
		Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64(8): 2865-73.
50:	Zoete V, Michielin O, Karplus M.
		Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors. J Comput Aided Mol Des. 2003 Dec;17(12):861-80.
51:	Zouhair A, Azria D, Pasche P, Stupp R, Chevalier J, Betz M, Mirimanoff RO, Ozsahin M.
		Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. Radiother Oncol 70(2): 183-8.

Dernière modification le 01.07.2008